2018-02-09 CDAMG Conference Call

back to CDA Management Group main page

HL7 CDAMG Minutes Location: Conference Call		Date: 2018-02-09 Time: 2:00 PM (ET)
Facilitator	Brett	Note taker(s)	Lisa

Attendee	Name
X	George Dixon
	Jean Duteau
X	Rick Geimer
	Kai Heitmann
X	Brett Marquard
X	Linda Michaelsen
	Dale Nelson
X	Lisa Nelson
	Andrew Statler
Quorum: Chair +3

Agenda & Minutes

• Welcome Guest: Austin Kreisler (Note: Call was not listed on the HL7 Conference Call Calendar)
• Agenda review
• Approve Minutes of 2018-01-29_CDAMG_WGM
• Review items
  • CDA R2.1 Style Sheet Creation PSS
  • CDA FHIR HAI PSS
• Discussion Topics
  • SWOT
    • Reviewed the SWOT
    • Any updates as a result of activity at the WGM?
    • Did we add: How do we manage quality problems for IG's that have already been published? Add as a Weakness list in SWOT.
    • Can we add: Threat and Opportunity - Trend toward mapping/developing FHIR and CDA interchange guidance simultaneously. Opportunity is to coordinate these efforts for consistency. Threat is decreased interoperability if not many simultaneous efforts produce divergent in inconsistent solutions
  • Asset List - Status, and ongoing management.
    • Discuss Status/Development toward CDA Template Interchage Format
    • Discuss Status of CDA Template Registry
    • What actions remain to be completed?
      • Review progress on CMG Wiki changes - what's left to be completed?
  • Discuss need for & Development of overall CDA Product Roadmap
    • Roadmap needs to address questions like:
      • Envisioned "superceeding" of CDA R2.0 with CDA R2.1 what it means to ANSI and HL7 Publishing and Implementer Use
      • Expectation for CDA R2.0 after CDA R2.1 is released?
      • What happens to C-CDA if CDA R2.0 is superceeded by R2.1?
      • Strategies for aligning C-CDA with FHIR?
  • Discuss Actions to be taken to solidify "check list procedure" for CMG members to use when reviewing PSSs, Document CMG PSS Review process to be followed (Jean)
    • Review minutes from 2018-01-29.
    • Is our plan sufficiently clear and actionable? Do we need to document the procedure(s) we will follow regarding where CMG approval is being injected into the HL7 approval processes?
  • Discuss Request to add a new member to CMG representing the Quality perspective (Lisa)
  • Discuss C-CDA Value Set Maintenance situation - what role needed from CMG? (Lisa)

Meeting Outcomes

Actions

Next Meeting/Preliminary Agenda Items TBD

© 2017 Health Level Seven® International. All rights reserved